treatment of newly diagnosed and relapsed hodgkin lymphoma in children
نویسندگان
چکیده
hodgkin lymphoma (hl) accounts for about 10% of all childhood cancers. five-year survival rates with modern therapies are now approaching >90-95% as a consequence of its significant sensitivity to both chemotherapy and radiation. the current challenge is to determine how much therapy is needed to improve survival and how to adapt treatment to the patient to prevent these long term toxicities. this challenge has resulted in the development of different strategies aimed at recognizing the optimal balance between preserving overall survival and avoidance of long-term treatment-related morbidity. strategies in children could be quite different from those used for adults with hl. more defined risk stratification through imaging studies and biologic markers have been developped. increased knowledge of the biology of hl have led to the introduction of targeted therapies in both the frontline and relapsed patients. collaborative multicenter studies are required to develop new combination therapies for children with newly diagnosed and refractory hl.
منابع مشابه
Treatment of Newly Diagnosed and Relapsed Hodgkin Lymphoma in Children
Hodgkin lymphoma (HL) accounts for about 10% of all childhood cancers. Five-year survival rates with modern therapies are now approaching >90-95% as a consequence of its significant sensitivity to both chemotherapy and radiation. The current challenge is to determine how much therapy is needed to improve survival and how to adapt treatment to the patient to prevent these long term toxicities. T...
متن کاملA phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
This study examines the activity and tolerability of a regimen combining vorinostat and rituximab in patients with indolent B-cell non-Hodgkin lymphoma. A total of 28 patients with newly diagnosed or relapsed/refractory follicular, marginal zone, or mantle cell lymphoma, with 4 or less prior therapies were eligible for this open-label phase II study. Oral vorinostat 200 mg was administered twic...
متن کاملNewly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
M. Dreyling1, M. Ghielmini2, R. Marcus3, G. Salles4, U. Vitolo5 & M. Ladetto6 on behalf of the ESMO Guidelines Working Group* Department of Medicine III, University of Munich, Munich, Germany; Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland; Haematology, Kings College Hospital, London, UK; Service D’Hématologie, Centre Hospitalier Lyon-Sud, Pierre-Beni...
متن کاملNewly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Diagnosis should always be based on a surgical specimen/ excisional lymph node biopsy. Core biopsies should only be performed in patients without easily accessable lymph nodes (e.g. retroperitoneal bulk). Fine needle aspirations are inappropriate for a reliable diagnosis. The histological report should give the diagnosis according to the WHO classification. Grading is performed according to the...
متن کاملHodgkin Lymphoma and Anaplastic Variants of Non-Hodgkin Lymphoma
Background and Objectives: Classic Hodgkin lymphoma (CHL), anaplastic large cell lymphoma (ALCL) and some cases of diffuse large B cell lymphoma (DLBCL) have overlapping morphologic features. Since they all represent distinct clinico-pathologic entities, we explored the differential diagnostic impact of immunophenotyping to discriminate between them. Materials and Methods:...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
iranian journal of blood and cancerجلد ۷، شماره ۵، صفحات ۲۰۶-۲۱۲
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023